You are here: Industry Insights > Novartis

News List

Novartis, TScan collaborate to develop TCR therapies for solid tumours pharmaceutical-business-review
April 20, 2020
Novartis has collaborated with TScan Therapeutics for the discovery and development of T cell receptor (TCR) therapies to treat solid tumours.
TScan and Novartis partner to develop cancer therapies pharmaceutical-technology
April 17, 2020
Biopharmaceutical firm TScan Therapeutics has signed an agreement with Novartis to discover and develop therapies for the treatment of cancer.
Novartis digital initiatives to create awareness of heart failure can positively impact patients’ lives in India: GlobalData expresspharma
April 15, 2020
According to GlobalData’s Pharma Intelligence Center, the diagnosed prevalence of congestive heart failure in India is currently around 9.61 million with an annual growth of 4 per cent.
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program worldpharmanews
April 08, 2020
Novartis announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi® (ruxolitinib) for treatment of a type of severe immune overreaction ...
Novartis and Incyte to trial Jakavi for Covid-19 pharmaceutical-technology
April 06, 2020
Novartis, in alliance with Incyte, has announced plans to evaluate Jakavi (ruxolitinib) in a Phase III clinical trial to treat cytokine storm in patients with severe Covid-19 pneumonia.
Novartis, Incyte to test Jakavi for coronavirus-linked cytokine storm pharmatimes
April 03, 2020
Novartis and Incyte are planning to launch a clinical study to test the potential of Jakavi (ruxolitinib) in patients with COVID-19 associated cytokine storm.
Novartis terminates $1bn Sandoz US deal with Aurobindo pharmaceutical-technology
April 03, 2020
Novartis and Aurobindo Pharma USA have signed a mutual agreement to terminate their deal covering the Sandoz US generic oral solids and dermatology businesses.
Study suggests Zolgensma will generate $2.5bn of global sales by 2025 europeanpharmaceuticalreview
April 01, 2020
According to researchers, Zolgensma, made by Novartis, will lead the global spinal muscular atrophy market and generate billions in sales.
Novartis, life sciences firms collaborate with BMGF to fight against COVID-19 disease pharmaceutical-business-review
March 31, 2020
Novartis and a consortium of life sciences companies have collaborated with Bill & Melinda Gates Foundation (BMGF) to advance the development, manufacture and delivery of vaccines, diagnostics and treatments for COVID-19.
Novartis gets positive CHMP opinion for Zolgensma and Cosentyx pharmaceutical-technology
March 31, 2020
Novartis has received a positive opinion from the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) for Zolgensma in spinal muscular atrophy (SMA), and Cosentyx in non-radiographic axial spondyloarthritis (nr-axSpA).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page